U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT06824649) titled 'Biologics in Chronic Rhinosinusitis with Nasal Polyposis' on Feb. 07.
Brief Summary: The prevalence of Chronic Sinusitis with Nasal Polyps (CRSwNP) in the United States is estimated at roughly 4%, which equates to over 13 million Americans. Until recently, the only medical treatment options available for patients with CRSwNP were corticosteroids, with surgery reserved for medical failure. The development of biologic medications over the last 5 years has revolutionized the treatment of CRSwNP. Three biologic medications have been FDA approved and available for the treatment of CRSwNP: dupilumab, omalizumab, and mepolizumab. However, ...